阿法骨化醇对早产儿骨密度的影响  

Effect of Alfacalcidol on Bone Density of Premature Infants

作　　者：任文娟[1] 张桂玲[1] 杨娅丽 赵会娟[1] 张怀强 张克勤[1] 孙许峰 方庆娟 贾茹茹 REN Wen-juan;ZHANG Gui-ling;YANG Ya-li;ZHAO Hui-juan;ZHANG Huai-qiang;ZHANG Ke-qin;SUN Xu-feng;FANG Qing-juan;JIA Ru-ru(Department of Pediatrics,Hospital of PLA 81st Group Army,Zhangjiakou,Hebei 075000,China;Zhangjiakou Maternal and Child Health Hospital,Zhangjiakou,Hebei 075000,China;The First Hospital of Zhangjiakou City,Zhangjiakou,Hebei 075000,China;People’s Hospital of Chongli District,Zhangjiakou,Hebei 076350,China)

机构地区：[1]中国人民解放军陆军第八十一集团军医院儿科,河北张家口075000 [2]河北省张家口市妇幼保健院,河北张家口075000 [3]张家口市第一医院,河北张家口075000 [4]张家口市崇礼区人民医院,河北张家口076350

出　　处：《河北北方学院学报（自然科学版）》2020年第6期13-15,共3页Journal of Hebei North University:Natural Science Edition

基　　金：张家口市科学技术研究与发展计划项目(No.1921110D)。

摘　　要：目的探讨阿法骨化醇对早产儿骨密度的影响。方法选择207例早产儿按照随机数字表法分为观察组104例和对照组103例,对照组给予维生素D滴剂口服,观察组给予阿法骨化醇口服,均连续用药3个月。比较2组血钙、血磷水平和骨密度的变化及不良反应。结果治疗后3个月,观察组血钙、血磷分别为(2.59±0.15)mmol·L-1、(1.51±0.10)mmol·L-1,对照组为(2.40±0.19)mmol·L-1、(1.34±0.09)mmol·L-1,观察组明显高于对照组(P<0.05);观察组矫正3月龄、6月龄骨密度分别为(0.51±0.04)g/cm3、(0.53±0.05)g/cm3,对照组分别为(0.46±0.05)g/cm3、(0.48±0.06)g/cm3,观察组明显高于对照组(P<0.05);治疗期间2组不良反应总发生率分别为5.77%和4.85%,差异无统计学意义(P>0.05)。结论阿法骨化醇可有效提高早产儿血钙、血磷水平,改善骨密度,具有较好的安全性,值得临床推广应用。Objective To investigate the effect of alfacalcidol on bone density of premature infants.Methods A total of 207 premature infants were divided into observation group(104 cases)and control group(103 cases)according to random number table method.The control group were given oral vitamin D drops,and the observation group oral alfacalcidol.The medication lasted three months.The changes of blood calcium,blood phosphorus levels,bone mineral density and adverse reactions were compared between the two groups.Results Three months after treatment,the blood calcium and phosphorus in the observation group were(2.59±0.15)mmol·L-1,(1.51±0.10)mmol·L-1,and(2.40±0.19)mmol·L-1,(1.34±0.09)mmol·L-1 in the control group,respectively;the levels in the observation group were significantly higher than those in the control group(P<0.05).The corrected bone density levels of the observation group at 3 months and 6 months were(0.51±0.04)g/cm3,(0.53±0.05)g/cm3,and(0.46±0.05)g/cm3,(0.48±0.06)g/cm3 in the control group,respectively;the levels in the observation group were significantly higher than those in the control group(P<0.05).During the treatment,the rates of adverse reactions in the two groups were 5.77%and 4.85%,respectively,but with no significant difference(P>0.05).Conclusion Alfacalcidol can effectively increase blood calcium and phosphorus levels in preterm infants,improve bone mineral density,and has good safety.It is worthy of clinical application.

关 键 词：早产儿 维生素D滴剂 阿法骨化醇 骨密度 

分 类 号：R722.6[医药卫生—儿科]